Leading the Fight Against Cancer
We equip students with the interdisciplinary education, laboratory experience and career skills they’ll need to excel in cancer research.
M.S. Info Sessions
The past two decades have seen a revolution in the study of cancer biology. Advances in molecular biology, biochemistry and cell biology have contributed to our understanding of malignant transformation, cancer prevention and cancer therapy. The Georgetown University Interdisciplinary Program in Tumor Biology provides doctoral and master’s students with an excellent academic environment and interdisciplinary training for a career in cancer biology research. Our students develop their potential to produce highest-quality research and academic scholarship.
Join Us in 2027!
Ph.D. Summer Admission Deadline: December 1
M.S. Fall Admission Early Application: January 15 – apply early to waive the application fee!
M.S. Fall Admission Priority Application: May 15
M.S. Fall Admission Final Deadline: July 1
Attend an online information session to learn about our programs:
The Georgetown Difference
Our program brings together about 60 faculty members from basic science and clinical departments, as well as the expertise and resources of Georgetown’s Lombardi Comprehensive Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center that combines excellence in basic and clinical cancer research, as well as research on cancer control and prevention.
A combination of formal courses, seminars, and ongoing collaborative research projects bring together faculty and trainees in a unified doctoral program committed to providing quality education in cancer biology, prevention, and therapy.
Alumni Success
Coursework, lab experience, mentorship and career development resources all empower our students to pursue impactful careers.
M.S. Alumni Outcomes M.S. and Ph.D. Career ServicesNews
NIH MSTP Award Advances Georgetown’s Vision for Physician-Scientist Training
From Norman J. Beauchamp Jr., Executive Vice President for Health Sciences and Executive Dean of the School of Medicine: Georgetown has been awarded its first National Institutes of Health (NIH) Medic…
August 5th, 2026
A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, ac…
July 30th, 2026
From Bowerbirds to Global Cancer Research: Christopher Loffredo Looks Back on a Four-Decade Career
The Cancer Prevention and Control Program at Lombardi Comprehensive Cancer Center hosted Loffredo’s valedictory lecture ahead of his transition to professor emeritus on July 1, 2026. Loffredo reflec…
July 15th, 2026